Tools for immuno-oncology biomarker research

The immuno-oncology field has significantly transformed with the development of immune-checkpoint inhibitors that show promising effects in the treatment of several cancer types. However, only a subset of patients exhibits durable responses to these treatment options. Biomarkers, which are biological diagnostic, predictive, and prognostic indicators, are crucial to enhance the benefits of existing and emerging immunotherapies, to a wider cohort of patients. Biomarkers offer valuable insights into patient selection, aiding drug development and personalized medicine. To support you in your biomarker discovery and validation studies, we offer a comprehensive suite of solutions including high quality, validated recombinant antibodies and assay kits.

Take a flexible approach

Our antibodies and assays for immuno-oncology targets are available in multiple formats: whether you are looking for a standard formulation, BSA-only formulation, conjugate, or sandwich or competitive ELISA kits, search our catalog to find the right format for your research.

Generate data you can trust

To give you specific and reproducible results, our antibodies and assays are supported by extensive data and validation in healthy and diseased tissues and in numerous applications. Our range of immuno-oncology products also includes knockout-validated antibodies for confirmed specificity and CRISPR-engineered knockout cell lines to validate your target or assay function. Our standard validation for IHC antibodies includes the use of tissue microarrays (TMAs) consisting of several types of normal and cancerous tissues. For added confidence in antibody specificity and sensitivity for drug development programs, our enhanced validation goes above and beyond, validating some of our best recombinant antibodies to clinically relevant clones, in a vastly increased number of cancer tissue cases and assays. Using FFPE cell lines with modulated target expression, peptide blocking assays, ELISA, and other bespoke assays, our enhanced validation provides ultimate confidence in an antibody clone. Up to 600 different disease cases are used to generate a detailed antibody analysis profile, and antibody sensitivity is evaluated with manual and digital target staining intensity analysis.

Our 90-minute, single-wash SimpleStep ELISA® (SSE) kits incorporate our recombinant antibodies for exceptional specificity and sensitivity. These SSE kits allow for the measurement of soluble biomarkers and have been validated for use with relevant biological fluids and sample types.

Whatever immuno-oncology target you are investigating, find the products you need in our extensive catalog.

Recombinant antibodies

Our catalogue of recombinant antibodies covers established and emerging biomarker targets, powered by your research insights and needs. These antibodies are extensively validated to ensure target specificity and selectivity in relevant tissue types, for your application of choice.

Our highly validated recombinant antibodies provide added confidence during biomarker discovery and validation studies, allowing you to accurately identify your proteins of interest and their functions, in your limited patient samples.

Our portfolio offers broad coverage, meaning we have antibodies for your target of interest. validated for your application of choice, in clinically relevant samples. Our application validation is extensive, especially for our IHC antibodies, which are routinely tested on TMAs consisting of 16 human normal and 16 human cancer tissues as well as TMAs of normal mouse and rat tissues, all in duplicates.

Product highlights

Target
Product name
abID
Notes
PD-1
Anti-PD1 antibody [CAL20]
ab237728
Validated for multiplex IHC. Reacts with human and rhesus monkey samples in IHC.
CTLA-4
Anti-CTLA4 antibody [CAL49]
ab237712
Validated for IHC with human and rhesus monkey samples
LAG-3
Anti-LAG-3 antibody [EPR20261]
ab209236
Top cited monoclonal antibody for IHC
TIM-3
Anti-TIM 3 antibody [EPR22241]
ab241332
Validated for multiplex IHC
HER2
Anti-ErbB2 / HER2 antibody [EP1045Y]
ab134182
Knock out validated
BRCA1
Anti-BRCA1 antibody [EPR19433]
ab213929
Suitable for IHC-P, ICC/IF with human samples
p53
Anti-p53 antibody [E26]
ab32389
Cited in >150 publications
Estrogen receptor alpha
Anti-Estrogen Receptor alpha antibody [E115] - ChIP Grade
ab32063
Top cited. Validated for ChIC/CUT&RUN-seq
Progesterone receptor
Anti-Progesterone Receptor antibody [SP2]
ab16661
Validated for multiplex IHC
BRAF (mutated v600E)
Anti-BRAF (mutated V600E) antibody [VE1]
ab228461
Top cited clone
PSMA
Anti-PSMA antibody [EPR6253]
ab133579
Top cited clone
MET
Anti-Met (c-Met) antibody [EP1454Y] - N-terminal
ab51067
Cited in >100 publications
TIGIT
Anti-TIGIT antibody [BLR047F] - BSA free
ab243903
Top cited clone for IHC
B7H4
Anti-B7H4 antibody [EPR20236]
ab209242
Enhanced validation in normal and tumor TMAs
STING
Anti-STING antibody [EPR13130-55]
ab239074
Enhanced validation in normal and tumor TMAs
EGFRvIII
Anti-EGFRvIII antibody [EPR28380-83]
ab313646
Enhanced validation in normal and tumor TMAs
Claudin 6
Anti-Claudin 6 [EPR28103-113] antibody
ab314134
Enhanced validation in normal and tumor TMAs
TROP2
Anti-TROP2 recombinant antibody [EPR20043]
ab214488
Enhanced validation in normal and tumor TMAs
SOX10
Anti-SOX10 recombinant antibody
ab180862
Enhanced validation in normal and tumor TMAs
VISTA
Anti-VISTA rabbit monoclonal antibody [EPR21050]
ab230950
Enhanced validation in normal and tumor TMAs

To explore our full range of Enhanced Validated IHC antibody clones

Click here
button-secondary

Assay kits

Biomarker analysis via non-invasive methods is urgently needed to monitor patient responses to immunotherapy. Soluble biomarkers that present in biological fluids overcome the limitations of using tissue biopsies. As such, there is growing interest in identifying serum biomarkers to predict immunotherapy outcomes, and several of these are under investigation.

Our SSE kits allow for the quantification of established and emerging soluble biomarkers during your preclinical and clinical studies.

Our highly sensitive and specific recombinant antibodies are used in our SSE kits to provide the same level of quality results for your ELISA studies. These kits are some of the fastest, sensitive, and convenient on the market, as they are optimized 90-minute assays with only a single-wash step. More importantly, they are validated for reactivity across various species using relevant biological sample types.

Product highlights

To explore our full range of SSE kits

Click here
button-secondary

Proteins

Our catalogue consists of over 13,000 proteins and peptides produced in several expression systems, validated across key applications. Over 12,000 of these are recombinantly produced, offering consistency across experiments, at the highest quality. Tagged formats of these proteins also exist for ease of use in your experimental setup.

Our recombinant and native proteins complement our antibodies and ELISA kits to give you comprehensive research solutions, with ease of integration into existing workflows.

Our proteins are made in various expression systems, allowing you to find the right protein that meets your experimental needs. Our highest quality premium grade bioactive proteins are mammalian-expressed, guaranteeing >95% purity and providing optimal bioactivity and stability at low endotoxin levels.

Product highlights

To explore our full range of proteins and peptides

Click here
button-secondary